Brief: Corvus Pharmaceuticals Announces Initiation Of Placebo-Controlled Phase 1 Clinical Trial Of Soquelitinib For Atopic Dermatitis
09/04/2024 21:19
April 9 (Reuters) - Corvus Pharmaceuticals Inc CRVS.O :
* CORVUS PHARMACEUTICALS ANNOUNCES INITIATION OF
PLACEBO-CONTROLLED PHASE 1 CLINICAL TRIAL OF SOQUELITINIB FOR
ATOPIC DERMATITIS
* CORVUS PHARMACEUTICALS INC: CORVUS ANTICIPATES RELEASING
INITIAL
CLINICAL DATA FROM TRIAL BEFORE YEAR-END 2024
* CORVUS PHARMACEUTICALS INC - CORVUS ANTICIPATES RELEASING
INITIAL CLINICAL DATA FROM TRIAL BEFORE YEAR-END 2024
* CORVUS PHARMACEUTICALS INC: TRIAL IS EXPECTED TO ENROLL 64
PATIENTS AT 12 SITES IN UNITED STATES
Source text for Eikon: ID:nGNX5f8x9X
Further company coverage: CRVS.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Corvus Pharmaceuticals
See all newsBrief: Corvus Pharmaceuticals Announces Initiation Of Phase 1B Clinical Trial Of Soquelitinib For Patients With Hidradenitis Suppurativa
Corvus Pharmaceuticals, Inc. reports results for the quarter ended June 30 - Earnings Summary
U.S. STOCKS ON THE MOVE-Cleveland-Cliffs, Ciena Corp, Nokia Oyj
U.S. STOCKS ON THE MOVE-Cleveland-Cliffs, Ciena Corp, Nokia Oyj
U.S. STOCKS ON THE MOVE-Toll Brothers, TG Therapeutics, CECO Environmental